ATE257378T1 - Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen - Google Patents
Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungenInfo
- Publication number
- ATE257378T1 ATE257378T1 AT99932179T AT99932179T ATE257378T1 AT E257378 T1 ATE257378 T1 AT E257378T1 AT 99932179 T AT99932179 T AT 99932179T AT 99932179 T AT99932179 T AT 99932179T AT E257378 T1 ATE257378 T1 AT E257378T1
- Authority
- AT
- Austria
- Prior art keywords
- phenylacetylisoglutamin
- treatment
- pharmaceutical composition
- phenyl acetate
- neoplastic diseases
- Prior art date
Links
- XBJLFHMAIQTBJX-JTQLQIEISA-N (4s)-5-amino-5-oxo-4-[(2-phenylacetyl)amino]pentanoic acid Chemical compound OC(=O)CC[C@@H](C(=O)N)NC(=O)CC1=CC=CC=C1 XBJLFHMAIQTBJX-JTQLQIEISA-N 0.000 title abstract 3
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000001613 neoplastic effect Effects 0.000 title abstract 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 title abstract 2
- 229940049953 phenylacetate Drugs 0.000 title abstract 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000001802 infusion Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/121,567 US6258849B1 (en) | 1998-07-23 | 1998-07-23 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| PCT/US1999/015017 WO2000004894A2 (en) | 1998-07-23 | 1999-07-02 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE257378T1 true ATE257378T1 (de) | 2004-01-15 |
Family
ID=22397538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99932179T ATE257378T1 (de) | 1998-07-23 | 1999-07-02 | Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6258849B1 (de) |
| EP (1) | EP1098643B1 (de) |
| JP (2) | JP2002521329A (de) |
| KR (4) | KR100417100B1 (de) |
| CN (3) | CN1191064C (de) |
| AT (1) | ATE257378T1 (de) |
| AU (1) | AU759278B2 (de) |
| BR (1) | BR9912356A (de) |
| CA (1) | CA2336945C (de) |
| DE (1) | DE69914084T2 (de) |
| DK (1) | DK1098643T3 (de) |
| EA (1) | EA004179B1 (de) |
| ES (1) | ES2214866T3 (de) |
| HK (1) | HK1037142A1 (de) |
| ID (1) | ID28160A (de) |
| IL (1) | IL140848A (de) |
| NZ (1) | NZ509244A (de) |
| PL (1) | PL213698B1 (de) |
| PT (1) | PT1098643E (de) |
| WO (1) | WO2000004894A2 (de) |
| ZA (1) | ZA200100622B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127419A (en) * | 1998-11-23 | 2000-10-03 | Burzynski; Stanislaw R. | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis |
| JP4163946B2 (ja) | 2000-08-29 | 2008-10-08 | バイオコン・リミテッド | 免疫調節性化合物およびその誘導体並びにそれを用いて疾患を治療する方法 |
| US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
| US20060246016A1 (en) * | 2003-05-28 | 2006-11-02 | Burzynski Stanislaw R | Toothpaste containing anticancer agents |
| US7087219B2 (en) * | 2003-05-28 | 2006-08-08 | Stanislaw R. Burzynski | Toothpaste containing anticancer agents |
| US7772108B2 (en) * | 2004-06-25 | 2010-08-10 | Samsung Electronics Co., Ltd. | Interconnection structures for semiconductor devices and methods of forming the same |
| ES2565848T3 (es) | 2004-07-07 | 2016-04-07 | Biocon Limited | Síntesis de compuestos inmunorreguladores unidos por grupos azoicos |
| US20060058383A1 (en) * | 2004-07-28 | 2006-03-16 | Peng Huang | Propyl 3-bromo-2-oxopropionate and derivatives as novel anticancer agents |
| CN102512408B (zh) * | 2004-11-26 | 2015-11-25 | Ucl商业有限公司 | 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物 |
| US20060205818A1 (en) * | 2005-03-08 | 2006-09-14 | Burzynski Stanislaw R | Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives |
| EP2413924B1 (de) * | 2009-04-03 | 2017-09-27 | Ocera Therapeutics, Inc. | L-ornithin-phenyl-acetat und verfahren zu seiner herstellung |
| CN102625699B (zh) | 2009-06-08 | 2014-08-20 | Ucl商业有限公司 | 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能 |
| EP2625162B1 (de) | 2010-10-06 | 2019-03-13 | Ocera Therapeutics, Inc. | Verfahren zur herstellung von l-ornithin-phenyl-acetat |
| CN113633777A (zh) | 2014-11-24 | 2021-11-12 | Ucl商业有限公司 | 使用降氨疗法治疗与肝星状细胞激活相关的疾病 |
| CA2995823A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| WO2017114686A1 (en) * | 2015-12-30 | 2017-07-06 | Nestec S.A. | Method for determining fat free body mass |
| US10624869B2 (en) * | 2017-05-08 | 2020-04-21 | Stanislaw R. Burzynski | Methods for the treatment of recurrent glioblastoma (RGBM) |
| JP7126520B2 (ja) | 2017-05-11 | 2022-08-26 | オセラ セラピューティクス， インコーポレイテッド | Ｌ－オルニチンフェニルアセテートを製造する方法 |
| KR20230124107A (ko) * | 2017-06-12 | 2023-08-24 | 스탠니슬로우 알 벌진스키 | 연수막 질환의 치료 방법 |
| US11344521B2 (en) | 2017-06-12 | 2022-05-31 | Burzynski Research Institute, Inc. | Methods for the treatment of leptomeningeal disease |
| CN116019798B (zh) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4470970A (en) | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
| US5254587A (en) | 1990-09-04 | 1993-10-19 | Burzynski Stanislaw R | Methods for treating AIDS |
| US5244922A (en) * | 1990-09-04 | 1993-09-14 | Burzynski Stanislaw R | Methods for treating viral infections |
| US5605930A (en) | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
| US6013278A (en) | 1996-05-14 | 2000-01-11 | Burzynski Research Institute | Liposomal antineoplaston therapies with markedly improved antineoplastic activity |
-
1998
- 1998-07-23 US US09/121,567 patent/US6258849B1/en not_active Expired - Fee Related
-
1999
- 1999-07-02 ES ES99932179T patent/ES2214866T3/es not_active Expired - Lifetime
- 1999-07-02 JP JP2000560887A patent/JP2002521329A/ja active Pending
- 1999-07-02 NZ NZ509244A patent/NZ509244A/xx not_active IP Right Cessation
- 1999-07-02 IL IL14084899A patent/IL140848A/xx not_active IP Right Cessation
- 1999-07-02 PT PT99932179T patent/PT1098643E/pt unknown
- 1999-07-02 KR KR10-2003-7002799A patent/KR100417100B1/ko not_active IP Right Cessation
- 1999-07-02 AU AU48542/99A patent/AU759278B2/en not_active Ceased
- 1999-07-02 CA CA002336945A patent/CA2336945C/en not_active Expired - Fee Related
- 1999-07-02 ID IDW20010174A patent/ID28160A/id unknown
- 1999-07-02 CN CNB99811314XA patent/CN1191064C/zh not_active Expired - Fee Related
- 1999-07-02 EP EP99932179A patent/EP1098643B1/de not_active Expired - Lifetime
- 1999-07-02 CN CNA2004100032827A patent/CN1605334A/zh active Pending
- 1999-07-02 WO PCT/US1999/015017 patent/WO2000004894A2/en active IP Right Grant
- 1999-07-02 DE DE69914084T patent/DE69914084T2/de not_active Expired - Lifetime
- 1999-07-02 AT AT99932179T patent/ATE257378T1/de active
- 1999-07-02 DK DK99932179T patent/DK1098643T3/da active
- 1999-07-02 KR KR10-2003-7002798A patent/KR100414587B1/ko not_active IP Right Cessation
- 1999-07-02 CN CNB2004100616005A patent/CN100400039C/zh not_active Expired - Fee Related
- 1999-07-02 EA EA200100168A patent/EA004179B1/ru not_active IP Right Cessation
- 1999-07-02 BR BR9912356-8A patent/BR9912356A/pt not_active Application Discontinuation
- 1999-07-02 KR KR10-2003-7002800A patent/KR100417101B1/ko not_active IP Right Cessation
- 1999-07-02 PL PL345959A patent/PL213698B1/pl unknown
- 1999-07-02 KR KR10-2001-7001021A patent/KR100399658B1/ko not_active IP Right Cessation
-
2001
- 2001-01-22 ZA ZA2001/00622A patent/ZA200100622B/en unknown
- 2001-05-22 US US09/863,035 patent/US6943192B2/en not_active Expired - Lifetime
- 2001-11-09 HK HK01107897A patent/HK1037142A1/xx not_active IP Right Cessation
-
2010
- 2010-10-08 JP JP2010228241A patent/JP2011051993A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE257378T1 (de) | Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen | |
| DE69230112D1 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
| DE69815122D1 (de) | Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen | |
| DE3684190D1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
| DE58901002D1 (de) | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken. | |
| DE69424777T2 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
| ATE77751T1 (de) | Mittel zur behandlung von knochenkrankheiten. | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| ATE208201T1 (de) | Verfahren zur behandlung von neoplastischen erkrankungen unter verwendung von tiazofurin und ribavirin | |
| DE50103012D1 (de) | Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen | |
| DE69943240D1 (de) | Verwendung von HGF für die Behandlung von ischämischen Erkrankungen der Extremitäten | |
| DE69434002D1 (de) | 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis | |
| DE69428797D1 (de) | Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden | |
| ATE335494T1 (de) | Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen | |
| DE59506911D1 (de) | Verwendung von intravenös applizierbarem eisen zur therapie von tumorerkrankungen und/oder infektionskrankheiten | |
| RU93019884A (ru) | Способ лечения острых гепатитов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1098643 Country of ref document: EP |